Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 24,740 shares, a decrease of 25.3% from the December 31st total of 33,109 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 181,623 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 181,623 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, BTIG Research reduced their price objective on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Xtant Medical currently has a consensus rating of “Buy” and a consensus target price of $1.50.

Xtant Medical Stock Down 3.0%

Xtant Medical stock traded down $0.02 during trading on Friday, reaching $0.59. 181,844 shares of the company’s stock were exchanged, compared to its average volume of 184,954. Xtant Medical has a 52-week low of $0.34 and a 52-week high of $0.95. The firm has a market cap of $82.88 million, a price-to-earnings ratio of 59.26 and a beta of -0.04. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The company’s 50-day moving average is $0.69 and its two-hundred day moving average is $0.68.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings data on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.The company had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $32.70 million.

Hedge Funds Weigh In On Xtant Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in shares of Xtant Medical during the second quarter valued at approximately $26,000. Mink Brook Asset Management LLC boosted its stake in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the period. Crescent Grove Advisors LLC grew its holdings in Xtant Medical by 94.3% during the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 200,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares during the period. Finally, AWM Investment Company Inc. purchased a new stake in Xtant Medical during the 2nd quarter worth $4,875,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.